Most vaccines in the world do not prevent infection from Omigran


The growing organization of preliminary research suggests that the Govt vaccines used in most countries of the world offer no protection against being exposed to the highly contagious Omigran variant.

All vaccines seem to provide a significant level of protection against serious diseases from Omicron, which is the most important goal. But only Pfizer and Moderna shots, reinforced by a booster, seem to have succeeded in stopping the infections, and these vaccines are not available in most countries of the world.

Other scenarios – including vaccines made by AstraZeneca, Johnson & Johnson and vaccines made in China and Russia – have done nothing to stop the spread of Omigran, early research shows. As most countries have developed vaccination programs around these vaccines, this gap could have a profound impact on the course of the epidemic.

In a world where billions of people are not vaccinated, the global outbreak of epidemics not only threatens the health of vulnerable individuals, but also increases the likelihood of many more variations. The imbalance in the capacity of countries to fight the epidemic will certainly deepen. News of the limited vaccine efficacy against Omigran infection may reduce the need for the vaccine worldwide, where many are already reluctant or involved in other health issues.

So far most of the evidence is based on laboratory tests that do not capture the full extent of the body’s immune response, and not from monitoring the effect on real-world populations. However, the results are surprising.

Pfizer and Moderna Shots use new mRNA technology that continues to provide excellent protection against infection of all kinds. All other vaccines are based on old methods of inducing immunity.

The Chinese vaccines Sinoform and Sinovac – which make up almost half of all shots given worldwide – provide almost zero protection against Omigran infection. These scenes, which are widely used in low- and middle-income countries such as Mexico and Brazil, are enjoyed by the majority of people in China.

Initial efficacy studies conducted in the UK showed that the Oxford-Astrogeneca vaccine did not show the ability to prevent omigran infection six months after vaccination. Ninety per cent of those vaccinated in India received the vaccine under the brand name Govshield; It is widely used in much of sub-Saharan Africa, where the global Govt vaccination program Kovacs has distributed 67 million doses to 44 countries.

Researchers predict that Russia’s Sputnik vaccine, which is also used in Africa and Latin America, will show similarly poor protection against Omigran.

Demand for this specialty has grown significantly as a result of recent corporate scandals in Africa. But it has shown little potential to prevent Omigran infection.

Antibodies are the first line to be triggered by vaccines. But early studies show that shots stimulate the growth of T cells, and that these T cells still recognize the Omigron variant, which is important in preventing acute disease.

“The first thing you lose is protection against asymptomatic mild infections, and the best you can have is protection against serious illness and death,” said John Moore, a virologist at Weil Cornell Medicine in New York. He called it “a silver lining” because Omigron was far less dangerous than the Delta variant.

But the director of the Center for Global Health Policy at the Center for International and Strategic Studies, J.J. Stephen Morrison said.

“The sheer size of the epidemic will overwhelm health systems because the divide will be so large,” he said. “If a global epidemic strikes you, what would the world be like on the other side of a shock?” Is it, ‘The war is over’ or, ‘The war has entered another phase’? We didn’t start thinking about it.

People with breakthrough events can only experience asymptomatic infections or mild illness, but they can also transmit the virus to those who have not been vaccinated, becoming seriously ill and becoming a source of new variants.

Dr. Gavi is the CEO of the Global Vaccine Alliance Gavi. Seth Berkeley said more data was needed before decisions could be made about the effectiveness of vaccines against Omicron – and that the accelerated vaccine should be central to the response to infection.

Preliminary data from South Africa suggest that those already infected with Govt disease with Omigran are more likely to re-infect than those with the original virus and previous variants. But some public health experts say there may be a buildup against omigran in countries already affected by the Govt waves, such as Brazil and India, and the vaccine produces higher antibody levels after infection.

“The combination of vaccine and virus exposure seems to be stronger than having a vaccine,” said Ramanan Laxminarayan, an epidemiologist in New Delhi. In India, the adult vaccination rate is only about 40 percent, but in some areas 90 percent are exposed to the virus.

“Without a doubt, Omigron is going to flood all over India,” he said. “But India is somewhat protected by vaccination and exposure.”

China does not have this protective layer to back up weak vaccines. Due to China’s aggressive efforts to prevent the spread of the virus within its borders, relatively few individuals have an earlier exposure. Only 7 percent of people in Wuhan are affected when the epidemic begins.

Much of Latin America is dependent on Chinese and Russian vaccines and AstraZeneca. Mario Rosamplot, a professor of immunology at the University of Chile, says more than 90 percent of people in Chile receive two doses of a single vaccine, but most of these are coronavac and synovac shot. High vaccine coverage combined with early reports that Omicron does not cause serious illness leads to a false sense of security in the country, he said.

“People need to understand that it’s not working like that: if you get more contagious, you’ve going to complete the health system because the number of sick people will be higher,” he said.

Brazil recommends a third dose for everyone who has been vaccinated, and it has begun to use Pfizer’s vaccine for all boosters, but only 40 percent of those who have been vaccinated have come forward to get an extra shot. Dr. Amilgar Tanuri, a virologist at the Federal University of Rio de Janeiro, was cautiously optimistic that the high level of previous Govt revelations could blunt the impact of Omigran, but noted that the most vulnerable Brazilians, who were first vaccinated, received coronavir and millions more. Also provided by AstraZeneca.

Mr. Morrison called Omigran’s ability to avoid vaccine protection for low- and middle-income countries a “major setback” where the focus is on delivering first impressions, without any discussion of boosters.

“The world is divided into two parts, isn’t it?” he said. “It’s the ones with the fastest path towards the boosters and the ones with the least progress and all of a sudden they are subject to this new lash.”

Just 13 percent of people in Africa have received at least one dose of the Govt vaccine.

Dr. Lakshminarayanan, to whom the Government of India, from time to time is an adviser, is considering booster shots, but the delta variant still poses a significant threat in India, and two vaccine doses provide protection against delta. Focusing on injecting two doses of unvaccinated, or only partially, vaccinated individuals presents a difficult choice for the government between the elderly and those with high-risk medical conditions and receiving stimulants for protection against Omicron.

The news that non-MRNA vaccines offer little protection against infection from Omigran could further reduce demand for shots in countries already struggling to generate demand, Mr. Morrison said.

“It challenges the full value of vaccines,” he said. “If you’re too backward, if you’re vulnerable, it’s feeding anti – vaccine sentiment and weakening confidence.”

Tolbert Nineswa, a senior researcher at the Johns Hopkins Bloomberg School of Public Health, said the growing threat to countries in the South that rely on non-MRNA vaccines is an accusation that rich countries have failed to help share that technology or develop production. Points in low and middle income countries.

As a result, dangerous variations from areas with low vaccine coverage will continue to emerge and the epidemic will continue, said Dr. Mohd.

Dr. in Poetry. Berkeley said it would be a grave mistake for countries to facilitate their vaccination drive or to assume that only MRNA vaccines are eligible for distribution.

“If developed countries do not like these vaccines, we see situations where countries say, ‘We do not want these vaccines,'” he said.

Lincy Soodell. Carl Zimmer And Emily Schmal Contributed report.


Leave a Comment